Table 2.
Results of the systematic literature review regarding median TSW in months
| Sacituzumab Govitecan [41] | Eribulin [40] | Capecitabine [40] | Vinorelbine | |
|---|---|---|---|---|
| GHS/QoL | 2.80 | 6.2 | 6.0 | -- |
| Physical functioning | 5.90 | -- | -- | -- |
| Role functioning | 2.10 | -- | -- | -- |
| Emotional functioning | 5.90 | -- | -- | -- |
| Cognitive functioning | 3.30 | -- | -- | -- |
| Social functioning | 3.30 | -- | -- | -- |
| Body image | -- | 6.7 | 6.0 | -- |
| Future perspective | -- | 6.0 | 4.8 | -- |
| Systemic therapy side-effects | -- | 4.9 | 7.2 | -- |
| Fatigue | 1.60 | 8.9 | 6.1 | -- |
| Nausea/vomiting | 2.10 | 9.9 | 6.5 | -- |
| Dyspnea | 6.90 | -- | -- | -- |
| Pain | 4.90 | 8.1 | 5.4 | -- |
| Diarrhea | 2.00 | 11.6 | 6.6 | -- |
| Appetite loss | 3.00 | -- | -- | -- |
| Constipation | 3.60 | -- | -- | -- |
| Insomnia | 4.10 | -- | -- | -- |
GHS - Global health status; QoL - Quality of life